Skip to main content

AstraZeneca’s Antibody Cocktail Is 83% Effective At Preventing Covid-19 Symptoms After Six Months, Trial Shows

Published 14 days ago
By Forbes

TOPLINE

AstraZeneca on Thursday said its Covid-19 prophylaxis drug is 83% effective in reducing the risk of symptomatic Covid-19 infections six months after being given, signaling that the antibody cocktail could be used as an effective means of preventing severe disease in individuals who may not develop a robust immune response to Covid-19 vaccines.

KEY FACTS

According to AstraZeneca, the antibody therapy called AZD7442 was also 88% effective in reducing the risk of severe Covid-19 or death when administered to Covid-19 infected patients within three days of symptom onset.

A separate follow-up of the prophylaxis’ phase three trials showed that the drug eliminated the risk of severe Covid-19 and deaths among all recipients over six months after a dose was administered.

The drugmaker noted that the trials used a 300-milligram dose of AZD7442 administered into the muscle to individuals who had not been exposed to Covid-19.

The antibody cocktail could prove to be an effective tool to protect people who may not develop a robust immune response after receiving Covid-19 vaccines.

CRUCIAL QUOTE

AstraZeneca’s chief of research and development, Mene Pangalos, said: “AZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of Covid-19 with one dose.”

BIG NUMBER

700,000. That’s the total number of doses of the antibody-drug that AstraZeneca has agreed to supply to the U.S. government in case it receives emergency use authorization from the U.S. Food and Drug Administration. The company sought FDA emergency approval for the drug back in October.

KEY BACKGROUND

AstraZeneca’s data from a fresh trial of the drug among already infected Covid-19 patients is encouraging, as a previous post-exposure trial in June suggested that AZD7442 failed to prevent symptoms. The June trial showed that the antibody cocktail was only 33% effective in individuals exposed to the virus—even including exposed individuals who tested negative—compared to a placebo. But Thursday’s announcement suggests that injection may prove to help reduce the severity of the disease in individuals who are already exposed. Despite encouraging numbers, AstraZeneca’s drug will likely have to show a significantly higher level of effectiveness than Merck and Pfizer’s antiviral pills which have also demonstrated the ability to significantly reduce the risk of deaths and severe disease in high-risk individuals. Antiviral pills are relatively cheaper and easier to produce compared to antibody treatments like AZD7442. Additionally, such pills can be administered orally to patients outside hospitals, making them a highly effective tool in places with limited healthcare infrastructure.

FURTHER READING

AstraZeneca’s Injectable Antibody Cocktail Halves Risk Of Death Or Developing Severe Covid, Trial Finds (Forbes)

Sign Up for Our Newsletter Daily Update

Get the best of Forbes Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.
Related Topics: #Africa, #Coronavirus, #Coronavirus Outbreak, #Coronavirus Pandemic, #COVID-19, #Featured, #News Letter, #newsletter, #Nigeria, #South Africa.